Literature DB >> 21167870

Cytokine disbalance in common human cancers.

Zoran Culig1.   

Abstract

Interleukin (IL)-6, -4, and -8 levels have been elevated in most patients suffering from prostate, breast, or colon cancer. There is a large body of evidence suggesting that chronic inflammation is one of the etiologic factors in these tumors. IL-6 is a multifunctional cytokine which is known to influence proliferation, apoptosis, and angiogenesis in cancer. Its transcription factor STAT3 is known as an oncogene that is constitutively phosphorylated in these malignancies. However, IL-6-induced STAT3 phosphorylation may result in growth arrest. IL-6 activation of androgen receptor in prostate cancer may yield either tumor cell proliferation or differentiation. Prolonged treatment with IL-6 results in generation of sublines which express a more malignant phenotype. Therapy options against IL-6 have been established and the antibody siltuximab has been applied in preclinical and clinical studies. Recently, investigations of the role of suppressors of cytokine signaling have been carried out. IL-4 and -8 are implicated in regulation of apoptosis, migration, and angiogenesis in cancers associated with chronic inflammation. All cytokines mentioned above regulate cellular events in stem cells. These cells could not be targeted by most conventional cancer therapies. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167870     DOI: 10.1016/j.bbamcr.2010.12.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  39 in total

Review 1.  Protein biomarkers of ovarian cancer: the forest and the trees.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Future Oncol       Date:  2012-01       Impact factor: 3.404

Review 2.  Mechanisms of action of isothiocyanates in cancer chemoprevention: an update.

Authors:  Sandi L Navarro; Fei Li; Johanna W Lampe
Journal:  Food Funct       Date:  2011-09-21       Impact factor: 5.396

3.  Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC.

Authors:  S A Almatroodi; C F McDonald; I A Darby; D S Pouniotis
Journal:  Cancer Microenviron       Date:  2015-08-30

Review 4.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

Review 5.  The role of cytokines in breast cancer development and progression.

Authors:  Marcela Esquivel-Velázquez; Pedro Ostoa-Saloma; Margarita Isabel Palacios-Arreola; Karen E Nava-Castro; Julieta Ivonne Castro; Jorge Morales-Montor
Journal:  J Interferon Cytokine Res       Date:  2014-07-28       Impact factor: 2.607

6.  STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.

Authors:  Benjamin L Bryson; Damian J Junk; Rocky Cipriano; Mark W Jackson
Journal:  Cell Cycle       Date:  2016-11-28       Impact factor: 4.534

7.  Detectability and reproducibility of plasma levels of chemokines and soluble receptors.

Authors:  Ilir Agalliu; Xiaonan Xue; Mary Cushman; Elaine Cornell; Ann W Hsing; Robert C Kaplan; Kathryn Anastos; Swapnil Rajpathak; Gloria Y F Ho
Journal:  Results Immunol       Date:  2013-08-05

8.  Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells.

Authors:  Monika A Davare; Sangeet Lal; Jennifer L Peckham; Suresh I Prajapati; Sakir H Gultekin; Brian P Rubin; Charles Keller
Journal:  Biochem Biophys Res Commun       Date:  2014-06-10       Impact factor: 3.575

9.  Interleukin-driven insulin-like growth factor promotes prostatic inflammatory hyperplasia.

Authors:  Alana M Hahn; Jason D Myers; Eliza K McFarland; Sanghee Lee; Travis J Jerde
Journal:  J Pharmacol Exp Ther       Date:  2014-10-07       Impact factor: 4.030

10.  Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer.

Authors:  Evan N Cohen; Tamer M Fouad; Bang-Ning Lee; Banu K Arun; Diane Liu; Sanda Tin; Angelica M Gutierrez Barrera; Toshihide Miura; Iwao Kiyokawa; Jun Yamashita; Ricardo H Alvarez; Vicente Valero; Wendy A Woodward; Yu Shen; Naoto T Ueno; Massimo Cristofanilli; James M Reuben
Journal:  Breast Cancer Res Treat       Date:  2019-05-03       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.